KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Equity Income: 2018-2020

Historic Equity Income for Arbutus Biopharma (ABUS) over the last 1 years, with Sep 2020 value amounting to -$2.5 million.

  • Arbutus Biopharma's Equity Income rose 27.53% to -$2.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$20.4 million, marking a year-over-year decrease of 43.56%. This contributed to the annual value of -$2.5 million for FY2020, which is 88.70% up from last year.
  • As of Q3 2020, Arbutus Biopharma's Equity Income stood at -$2.5 million, which was up 76.92% from -$11.0 million recorded in Q4 2019.
  • Over the past 5 years, Arbutus Biopharma's Equity Income peaked at -$2.5 million during Q3 2020, and registered a low of -$11.0 million during Q4 2019.
  • In the last 3 years, Arbutus Biopharma's Equity Income had a median value of -$3.3 million in 2019 and averaged -$4.4 million.
  • Per our database at Business Quant, Arbutus Biopharma's Equity Income slumped by 304.74% in 2019 and then grew by 27.53% in 2020.
  • Quarterly analysis of 3 years shows Arbutus Biopharma's Equity Income stood at -$2.7 million in 2018, then crashed by 304.74% to -$11.0 million in 2019, then increased by 27.53% to -$2.5 million in 2020.
  • Its Equity Income was -$2.5 million in Q3 2020, compared to -$11.0 million in Q4 2019 and -$3.5 million in Q3 2019.